drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
A HER2-targeted antibody–drug conjugate linking the anti-HER2 antibody disitamab to the microtubule inhibitor monomethyl auristatin E (MMAE) via a cleavable linker; upon HER2 binding and internalization, MMAE is released to disrupt microtubules, causing G2/M arrest and apoptosis with a potential bystander effect.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Disitamab Vedotin
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
HER2-targeted antibody–drug conjugate linking disitamab to the microtubule inhibitor MMAE via a cleavable linker; upon HER2 binding and internalization, the linker is cleaved to release MMAE, which inhibits tubulin polymerization, causing microtubule disruption, G2/M arrest, and apoptosis, with a potential bystander effect.
drug_name
Disitamab Vedotin (RC48)
nct_id_drug_ref
NCT06572319